ArticleClinical nephrology2025
Using resorbable extracellular bio-matrix for construction and reconstruction of hemodialysis vascular access.
Article in Clinical nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe assessed the use of resorbable extracellular bio-matrix in vascular access surgery. MATERIALS AND
methodsA retrospective analysis was made of procedures where a resorbable extracellular bio-matrix was used for the construction or reconstruction of an arteriovenous (AV) fistula. A tubular shape of a certain length and diameter was made from sheets of resorbable bio-matrix (CorMatrix), which was then incorporated into AV anastomosis. Puncturing for hemodialysis began 8 - 10 weeks after construction.
resultsSince 2016, our unit has used resorbable extracellular bio-matrix in 22 patients. We used it as an arterial circuit to the AV fistula vein, a reduction segment in high-flow AV fistulas, to extend the puncture area, as a connecting segment after partial removal of an AV fistula, and to construct the entire AV fistula instead of a graft. All procedures were successful with no significant peri- or post-operative complications. Additional procedures to ensure patency were also successfully performed. Histopathological analysis showed complete vascular differentiation of the bio-matrix resulting in thickening of the wall and narrowing of the lumen.
conclusionThe use of resorbable extracellular bio-matrix in vascular surgery is safe and feasible. It is recommended to use wider grafts to avoid thrombosis due to narrowing of the lumen. Further research and pre-prepared tubular bio-grafts of different diameters and lengths are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.